


Appl. No. 09/916,136
Amendment Dated November 29, 2004
Reply to Office Action of September 21, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Rocha et al.) TC/A U 1617
SERIAL NO.: 09/916,136) CONFIRMATION NO.: 8218
EXAMINER: Shengjun Wang) ATTORNEY DOCKET NO.: 3357/1/US
FILED: 07/26/2001)
TITLE: ALDOSTERONE BLOCKER THERAPY TO PREVENT OR TREAT
INFLAMMATION-RELATED DISORDERS

CERTIFICATE OF MAILING

I hereby certify that this communication and any recited enclosures are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 29, 2004.


Linda K. Cooper

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT

Sir:

This letter is in response to the Office Action dated September 21, 2004, having a Shortened Statutory Period for Response that was set to expire on December 21, 2004.



The Applicants believe that this response is timely made, however, please charge any appropriate fees to Deposit Account No 19-1025. Please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims that begins on page 3 of this paper.

Remarks/Arguments begin on page 7 of this paper.

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the Application.

AMENDMENT TRANSMITTAL LETTER (Large Entity)					Docket No. 3557/1/US	
Applicant(s): Ricardo Rocha et al. DEC 01 2004						
Application No. 09/916,136	Filing Date July 26, 2001	Examiner Shengjun Wang	Customer No. 26648	Group Art Unit 1617	Confirmation No. 8218	
Invention: ADOSTERONE BLOCKER THERAPY TO PREVENT OR TREAT INFLAMMATION-RELATED DISORDERS						
COMMISSIONER FOR PATENTS:						
Transmitted herewith is an amendment in the above-identified application.						
The fee has been calculated and is transmitted as shown below.						
CLAIMS AS AMENDED						
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE	
TOTAL CLAIMS	7 -	71 =	0 x	\$18.00	\$0.00	
INDEP. CLAIMS	1 -	2 =	0 x	\$88.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00	
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00	
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 19-1025 <input type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038.						
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
 Signature			Dated: November 29, 2004			
Philip B. Polster II, Reg. No. 43,864 Pharmacia Corporation of Pfizer Inc. P.O. Box 1027 Chesterfield, Missouri 63006 314.274.9094			<div style="border: 1px solid black; padding: 5px;"> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on <u>November 29, 2004</u> (Date)  Signature of Person Mailing Correspondence Linda K. Cooper Typed or Printed Name of Person Mailing Correspondence </div>			
CC:						